Summary & Overview
CPT 55881: Transurethral Ultrasound Ablation (TULSA) of Prostate Tissue
CPT code 55881 defines the use of a transurethral ultrasound transducer previously inserted in the urethra to perform transurethral ultrasound ablation (TULSA) of prostate tissue under magnetic resonance imaging (MRI) guidance. This technologically advanced, image-guided ablative procedure is important nationally as an option for focal or whole-gland prostate tissue ablation that leverages MRI for real-time targeting and monitoring.
Key payers evaluated include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage and reimbursement for MRI-guided TULSA vary across commercial carriers and Medicare policy. Readers will find clinical context for the procedure, payer coverage patterns, common billing modifiers, and benchmarking where available. The publication outlines the service setting expectations, typical clinical indications, and coding considerations tied to device- and image-guided prostate ablation.
This summary equips clinicians, billing professionals, and policy analysts with a concise reference to the procedure represented by CPT code 55881, the typical sites of service, the major payers addressed in the analysis, and the scope of topics covered including policy implications and coding practice notes. Data not available in the input will be identified where applicable.
Billing Code Overview
CPT code 55881 describes use of a transducer previously inserted in the urethra for transurethral ultrasound ablation (TULSA) of prostate tissue. Service type: Image-guided minimally invasive prostate tissue ablation using a transurethral ultrasound transducer. Typical site of service: Hospital outpatient department or ambulatory surgery center with magnetic resonance imaging (MRI) guidance available for the procedure.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old man with symptomatic benign prostatic hyperplasia (BPH) or localized prostate cancer who has persistent lower urinary tract symptoms or focal prostate malignancy despite medical therapy and who prefers a minimally invasive, gland-preserving option. The patient undergoes pre-procedure evaluation including history and physical, prostate-specific antigen (PSA) testing, urinary flow rate measurement, and prostate imaging (multiparametric MRI). On the day of service the patient is brought to an MRI suite equipped for interventional procedures. Under conscious sedation or monitored anesthesia care, a transrectal or transurethral device (transducer) is placed in the urethra and positioned within the prostate under MRI visualization. The interventional urologist or radiologist performs real-time MRI-guided transurethral ultrasound ablation (TULSA) to target and thermally ablate prostatic tissue while monitoring temperature and anatomic boundaries on MRI sequences. Post-ablation MRI scans confirm the treated zone. The patient is recovered in a post-anesthesia area, receives short-term catheter drainage as indicated, and is discharged with follow-up plans for PSA surveillance, symptom assessment, and imaging as clinically warranted.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard reporting | Use when no specific modifier applies to the service. |